スタッフ紹介

  1. ホーム
  2. 概要
  3. スタッフ紹介
  4. 豊嶋崇徳

教授

豊嶋 崇徳 Teshima Takanori

血液内科学教授
昭和61年卒

略歴

1980年 鳥取県立米子東高等学校卒業
1986年 九州大学医学部卒業
1992年 唐津赤十字病院　内科
1993年 北九州市立医療センター　内科
1996年 岡山大学第二内科助手
1997年 米国Harvard大学Dana-Farber Cancer Institute研究員
1999年 米国Michigan大学がんセンター研究員
2000年 米国Michigan大学内科ファカルティー
2002年 岡山大学病院　血液・腫瘍・呼吸器・アレルギー内科助手
2004年 九州大学病院　遺伝子・細胞療法部　准教授
2010年 文部科学省　研究振興局　学術調査官併任
2012年 北海道大学大学院　医学研究科　内科学講座　血液内科学　教授
2014年 国際医療部長
2016年 HIV診療支援センター長
2017年 造血幹細胞移植連携支援センター部長
2018年 北海道大学病院　検査・輸血部　部長
2020年 北海道大学病院　超音波センター長
2023年 北海道大学　卓越教授

賞罰

1999年 米国造血細胞移植学会　最高論文賞
2016年 平成27年度北海道大学大学院医学研究科・医学部医学科　優秀研究賞
2019年 第1回日本造血細胞移植学会学会賞
2020年 第3回伊藤太郎特別賞
2021年 令和2年度 北海道大学教育研究総長表彰
2021年 防災・減災×サステナブル大賞サステナブル部門　グローバル賞
2021年 第75回北海道新聞文化賞
2022年 第11回日本血液学会賞
2022年 第74回保健文化賞
2023年 令和4年度北海道科学技術賞
第48回井上春成賞

所属学会

専門領域

血液学，造血細胞移植学，輸血学，検査医学, 免疫学

業績

  1. Teshima. CNS involvement in ATL. Cancer 1990.
  2. Nagafuji. Hematopoietic progenitor cells from patient with ATL are not infected with HTLV-I. Blood 1993.
  3. Teshima. BMT for EBV-associated NK cell-large granular lymphocyte leukemia. Lancet 1996.
  4. Hill. IL-11 promotes T cell polarization and prevents acute GVHD after allogeneic BMT. J Clin Invest 1998.
  5. Teshima. IL-11 separates GVL effects from GVHD after BMT. J Clin Invest 1999.
  6. Hill. Differential roles of IL-1 and TNF-α on GVHD and GVL. J Clin Invest 1999.
  7. Pan. G-CSF-mobilized allogeneic SCT maintains GVL effects through a perforin dependent pathway while preventing GVHD. Blood 1999.
  8. Krijanovski. Keratinocyte growth factor separates GVL effects from GVHD. Blood 1999.
  9. Reddy. IL-18 regulates acute GVHD by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001.
  10. Cooke. LPS antagonism reduces GVHD and preserves GVL activity after BMT. J Clin Invest 2001.
  11. Teshima. Tumor cell vaccine elicits potent anti-tumor immunity after allogeneic T-cell depleted BMT. Cancer Res 2001.
  12. Teshima. Acute GVHD does not require alloantigen expression on host epithelium. Nat Med 2002.
  13. Ordemann. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute GVHD. J Clin Invest 2002.
  14. Teshima. Flt3 ligand therapy for recipients of allogeneic BMT expands host CD8α+ dendritic cells and reduces acute GVHD. Blood 2002.
  15. Teshima. DLI from immunized donors increases tumor vaccine efficacy after allogeneic BMT. Cancer Res 2002.
  16. Reddy. IL-18 preserves perforin dependent GVL effect after allogeneic BMT. Blood 2002.
  17. Teshima. Impaired thymic negative selection causes autoimmune GVHD. Blood 2003.
  18. Reddy. Pretreatment of donors with IL-18 attenuates acute GVHD via STAT6 and preserves GVL effects. Blood 2003.
  19. Ichiba. Early changes in gene expression profiles of hepatic GVHD uncovered by ologonucleotide microarrays. Blood 2003
  20. Maeda. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute GVHD. Blood 2005.
  21. Matsuoka. Fetal tolerance to maternal antigens improves the outcome of allogeneic BMT by a CD4+CD25+ T cell-dependent mechanism. Blood 2006.
  22. Sakoda. Donor-derived thymic-dependent T cells cause chronic GVHD. Blood 2007.
  23. Koyama. Plasmacytoid dendritic cells prime alloreactive T cells to mediate GVHD as antigen-presenting cells. Blood 2009.
  24. Aoyama. Improved outcome of allogeneic BMT due to breast-feeding-induced tolerance to maternal antigens. Blood 2009.
  25. Asakura. Alloantigen expression on non-hematopoietic cells reduces GVL effects. J Clin Invest 2010.
  26. Kikushige. TIM-3 is a promising target to selectively kill AML stem cells. Cell Stem Cell 2010.
  27. Teshima. Th1 and Th17 join forces for acute GVHD. Blood 2011.
  28. Takashima. The Wnt agonist R-spondin1 regulates systemic GVHD by protecting intestinal stem cells. J Exp Med 2011.
  29. Hashimoto. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic HSCT. J Exp Med 2011. 
  30. Ferrara. Regenerating islet-derived 3α is a biomarker of gastrointestinal GVHD. Blood 2011.
  31. Nishimori. Synthetic retinoid Am80 ameliorates chronic GVHD by downregulating Th1 and Th17. Blood 2012. 
  32. Harris. Plasma biomarker of loser gastrointestinal and liver acute GVHD. Blood 2012.
  33. Eriguchi. GVHD disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood 2012.
  34. Kuriyama. Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis. Blood 2012.
  35. Shima. Quantification of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic SCT. Blood 2013.
  36. Aoyama. Inhibiting retinoic acid signaling ameliorates GVHD by modifying T-cell differentiation and intestinal migration. Blood 2013.
  37. Teshima. JAK inhibitors: a home run for GVHD patients? Blood 2014.
  38. Teshima. The primacy of IL-6 in IPS? Blood 2015.
  39. Uryu. α-Mannan induces Th17-mediated pulmonary GVHD in mice. Blood 2015.
  40. Sugita: HLA-haploidentical PBSCT with posttransplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant 2015.
  41. Teshima. Acute GVHD: Novel biological insights. Biol Blood Marrow Transplant 2016.
  42. Shimoji. GVHD targets ovary and causes female infertility in mice. Blood 2017.
  43. Hayase. R-Spondin1 expands Paneth cells and prevents dysbiosis induced by GVHD. J Exp Med 2017.
  44. Yamakawa. Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic GVHD. Blood 2018.
  45. Takahashi. Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine GVHD. Blood 2018. 
  46. Mathew. Sorafenib promotes GVL activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 2018.
  47. Schuster. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019.
  48. Noviello. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun 2019.
  49. Toffalori. Immune signature drives leukemia escape and relapse after HSCT. Nat Med 2019.
  50. Stein-Thoeringer. Lactose drives Enterococcus expansion to promote GVHD. Science 2019.
  51. Peled, et al. Microbiota as predictor of mortality in allogeneic HCT. N Engl J Med 2020.
  52. Ara T. Intestinal goblet cells protect against GVHD after allogeneic SCT via Lypd8. Sci Transl Med 2020.
  53. Yokota. Mass screening of asymptomatic persons for SARS-CoV-2 using saliva. Clin Infect Dis 2021.
  54. Yokota. A novel strategy for SARS-CoV-2 mass-screening using quantitative antigen testing of saliva: a diagnostic accuracy study. Lancet Microbes 2021.
  55. Yokota. Logistic advantage of two-step screening strategy for SARS-CoV-2 at airport quarantine. Travel Med Infect Dis. 2021.
  56. Chakraverty, Teshima. GVHD: a disorder of tissue regeneration and repair. Blood 2021.
  57. Zeiser, Teshima. Nonclassical manifestations of acute GVHD. Blood 2021.
  58. Zeiser. Ruxolitinib for glucocorticoid-refractory chronic GVHD. N Engl J Med. 2021.
  59. Schuster. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021.
  60. Ishio. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. Blood 2022
  61. Shimura: Multiple introductions of SARS-CoV-2 B.1.1.214 lineages from mainland Japan preceded the third wave of the COVID-19 epidemic in Hokkaido. Travel Med Infect Dis 2021
  62. Fowler. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022.
  63. Wang. Ibrutinib plus bendamustine and rituximab in untreated Mantle-cell lymphoma. N Engl J Med 2022.
  64. Chiba: Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. Blood 2022.
  65. Benjamin. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a phase 1, dose-escalation trial. Lancet Haematol 2022.
  66. Chen. Reactive granulopoiesis depends on T-cell production of IL-17A and neutropenia-associated alteration of gut microbiota. Proc Natl Acad Sci USA 2022.
  67. Inoue. Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. J Exp Med 2023.
  68. Miklos. Ibrutinib for first-line treatment of chronic GVHD: Results from the randomized phase III iNTEGRATE Study. J Clin Oncol 2023.
  69. Grupp. Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome: a randomised, multicentre, phase 3 trial. Lancet Haematol 2023.
  70. Senjyo. Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT. Blood 2023.

詳細はresearch map個人ページを参照してください。

research map

コメント

情熱にあふれる若者と将来を語りあうのが何より楽しみです。